Previous close | 15.00 |
Open | 16.25 |
Bid | 16.10 |
Ask | 16.65 |
Strike | 190.00 |
Expiry date | 2025-02-21 |
Day's range | 15.80 - 16.25 |
Contract range | N/A |
Volume | |
Open interest | 151 |
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 (September 13-17, 2024). Presentations include data on mirvetuximab soravtansine (ELAHERE®) and c-Met targeting ADCs, telisotuzumab vedotin (Teliso-V) and telisotuzumab adizutecan (ABBV-400). AbbVie's ADCs are designed to target protein biomarkers such as folate receptor-alpha (FRα) and c-Met (MET
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.